Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -40.70% | -388.61% | -119.74% | 17.17% | 53.81% |
| Total Depreciation and Amortization | -10.42% | 3.64% | 3.32% | 2.72% | 20.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 146.69% | 105.98% | 277.15% | -57.11% | -153.03% |
| Change in Net Operating Assets | -163.74% | 149.12% | -135.22% | 312.52% | 179.90% |
| Cash from Operations | 0.49% | 26.54% | 16.38% | 24.66% | 12.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -48.64% | -- | -- | -- |
| Total Debt Repaid | 93.12% | 38.52% | -3,285,590.91% | -840,425.58% | -456,886.49% |
| Issuance of Common Stock | 90.31% | 109.56% | 0.12% | -19.81% | -44.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -549.13% | -- | -- | -- | -- |
| Cash from Financing | 81.91% | 93.82% | -5.31% | -25.43% | -47.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 110.12% | 100.48% | 163.92% | 19.14% | -1,272.56% |